AbbVie Inc. (ABBV) — closed signal from October 20, 2025
Partial Published before the outcome was known, scored automatically when the window closed on January 18, 2026.
Predicted vs. what happened
What happened
Reached 33% of the predicted growth at its peak, without hitting the target.
The thesis — published October 20, 2025
AbbVie looks like it dropped more than usual and could bounce over the next 1-3 months. Fresh news that it bought rights to a new psychiatry drug lifts the mood after several down days. The company generates steady, defensive cash, which can help steady the stock. Signs of a turn are not fully in place yet, so the rebound case improves if price and trading interest begin to firm up from here.
Primary drivers
- New psychiatry drug deal strengthens pipeline and may lift future sales
- Stock fell too far too fast and may move back toward a more typical range
- Investor mood is positive, which can draw more interest to the shares
- Strong, predictable cash flow helps during uncertain market conditions
How it played out
ABBV: thesis missed the target
Lyra published ABBV at $231.75 on 2025-10-20 with expected growth of 10%. The thesis pointed to a psychiatry drug deal, a stock that had fallen too far too fast, positive investor mood, and steady defensive cash flow. It was a rebound case over the short-term window.
Inside the window, ABBV peaked at $239.29 on 2025-11-13, a 3.3% gain. It stayed below the $254.93 target and never reached it. By 2026-01-18, it ended at $214.35. The thesis only partly played out early, then missed.
What happened during the window
On 2025-10-31, AbbVie reported third-quarter 2025 results, including $15.78 billion in revenue and adjusted earnings of $1.86 per share. On 2026-01-13, The Wall Street Journal reported that AbbVie had reached a deal with the Trump administration involving a $100 billion U.S. investment plan and lower Medicaid prices.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.